CVA Family Office’s Vaxcyte PCVX Stock Holding History

CVA Family Office’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15	Closed	-$488	–	1333
2025 Q2	$488	Buy	15 +8	+114%	+$262	﹤0.01%	1241
2025 Q1	$264	Buy	+7	New	+$560	﹤0.01%	1372

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

CVA Family Office's PCVX Position: Q3 2025 in Review

CVA Family Office sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 15 shares — an estimated $488 sold.

CVA Family Office first reported a position in PCVX in Q1 2025 and held it in 2 quarters. The position peaked at $488 in Q2 2025. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

CVA Family Office reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
CVA Family Office sold 15 Vaxcyte shares in Q3 2025, an estimated $488.
CVA Family Office first reported a position in Vaxcyte in Q1 2025 and held it in 2 quarters.
CVA Family Office's Vaxcyte position peaked at $488 in Q2 2025.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on CVA Family Office's 13F filing for Q3 2025, filed 30 Oct 2025.